Abstract

This article presents results of the introduction in practical oncology of molecular genetic investigations performed with the use of tumor DNA cells taken from the cytological specimens. There was investigated the molecular genetic characteristics of cytological specimens from 126 patients. In 80 cases with the proved diagnosis of pulmonary adenocarcinoma (n = 80) EGFR gene mutations were noted in 11.7% cases. KRAS, BRAF and BRCA1/2 gene mutations were determined in 46 women suffering from serous ovarian carcinoma. KRAS gene mutations in cells of ovarian low-grade serous carcinoma were determined in 62.5% of patients, BRAF- in 12.5% cases. BRCA1 gene mutations have been determined in 14.3% cases from the ovarian high-grade serous carcinoma group. In conditions of the presence of the sufficient amount of tumor cells the cytological material is the fully-featured material for molecular genetic investigations. The investigation both of EGFR gene mutations in pulmonary adenocarcinoma cases and KRAS, BRAF, BRCA1/2 gene mutations with serous ovarian carcinoma are mandatory in the appointment of targeted therapy.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.